{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8"],"submitter":["Schutte M"],"pubmed_abstract":["Colorectal carcinoma represents a heterogeneous entity, with only a fraction of the tumours responding to available therapies, requiring a better molecular understanding of the disease in precision oncology. To address this challenge, the OncoTrack consortium recruited 106 CRC patients (stages I-IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totalling >4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of 106 tumours, 35 organoids and 59 xenografts, with extensive omics data comparing donor tumours and derived models provides a resource for advancing our understanding of CRC. Models recapitulate many of the genetic and transcriptomic features of the donors, but defined less complex molecular "],"journal":["Nature communications"],"pagination":["14262"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5309787"],"repository":["biostudies-literature"],"pubmed_title":["Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors."],"pmcid":["PMC5309787"],"pubmed_authors":["Nilsson M","Borodina T","Herwig R","Becker M","Amstislavskiy V","Abdavi-Azar N","Butcher LM","Wierling C","Reinhard C","Schweiger C","Velasco JA","Garin-Chesa P","Lehrach H","Yildiriman R","Welte Y","Wienke D","Lange M","Schumacher D","Silvestrov M","Kessler T","Golob-Schwarzl N","Uranitsch S","Keilholz U","Regan JL","Beck S","Schafer R","Landegren U","Lange B","Lax S","Yaspo ML","Worth CL","Liebs S","Barrett JE","Sultan M","Haybaeck J","Kehler I","Regenbrecht CR","Keil M","Warnatz HJ","Boehnke K","Hoffmann J","Schutte M","Henderson D","Risch T","Jandrasits C","Fusi A"],"additional_accession":[]},"is_claimable":false,"name":"Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.","description":"Colorectal carcinoma represents a heterogeneous entity, with only a fraction of the tumours responding to available therapies, requiring a better molecular understanding of the disease in precision oncology. To address this challenge, the OncoTrack consortium recruited 106 CRC patients (stages I-IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totalling >4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of 106 tumours, 35 organoids and 59 xenografts, with extensive omics data comparing donor tumours and derived models provides a resource for advancing our understanding of CRC. Models recapitulate many of the genetic and transcriptomic features of the donors, but defined less complex molecular ","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Feb","modification":"2026-04-28T23:23:53.29Z","creation":"2019-03-27T02:36:33Z"},"accession":"S-EPMC5309787","cross_references":{"pubmed":["28186126"],"doi":["10.1038/ncomms14262"]}}